Disclosed are novel nitrilated psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The compounds may be produced by reacting a reactant psilocybin derivative with a nitrile-group containing compound.

Disclosed are novel nitrated psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The nitrated psilocybin derivative compounds may be chemically synthesized or biochemically synthesized in host cells.

Disclosed are novel prenylated psilocybin derivative compounds and pharmaceutical and recreational drug formulations containing the same. The compounds may be produced in vitro or in vivo using a biosynthetic system which comprises cells comprising a prenyl transferase, and, optionally, additional enzymes, including a decarboxylase, and an N-acetyl transferase.

Provided herein are engineered decarboxylase polypeptides that are useful for catalyzing the decarboxylation of amino acids such as L-tyrosine to produce tyramine or catalyzing the decarboxylation of L-DOPA to produce dopamine. Also provided are the preparation process of engineered decarboxylase polypeptides as well as reaction process under industrial-relevant conditions. The disclosure also provides polynucleotide sequences encoding engineered decarboxylase polypeptides, recombinant host cells capable of expressing engineered decarboxylase polypeptides, and methods of producing tyramine or dopamine using the engineered decarboxylase polypeptides. Compared to the wild type decarboxylase, the engineered polypeptide provided by this disclosure has better activity and/or stability. The use of the engineered polypeptides for the preparation of tyramine or dopamine reduces the production cost and has a good industrial application prospect.

The invention provides a composition for use as a medicament, comprising cells of a recombinant microorganism capable of producing increased amounts of one or more of 5-hydroxytryptophan (5-HTP), 5-hydroxytryptamine (5-HT) and tryptamine (TRM) as compared to the non-recombinant microorganism from which it was derived. The composition finds use in preventing and/or treating TRM-; 5-HTP-, or 5-HT-related disorders of the central nerve system (CNS); enteric nervous system (ENS); gastro intestine (GI) and metabolism in a mammal, and may be orally administered to a mammal in need thereof. Additionally, a composition comprising cells of a recombinant microorganism capable of producing melatonin is provided for use as a medicament, such as for treatment of depression, dementia, cancer and sleep disorder.

Provided herein are biocatalysts and systems thereof for pterin-dependent enzymes and pathways and methods of making and using the same. Provided herein in some embodiments are biocatalysts having a pterin source and a pterin-dependent enzymatic pathway biologically coupled to the pterin source. Tetrahydrobiopterin (referred to herein as BH4 or BH 4) can be the pterin source. The BH4 can be synthesized by a tetrahydrobiopterin synthesis pathway. The tetrahydrobiopterin synthesis pathway can include a GTP cyclohydrase; a pyruvoyl tetrahydropterin synthase; a sepiapterin reductase, and/or any combination thereof. The biocatalyst can further contain a pterin-dependent enzymatic pathway. The pterin-dependent enzymatic pathway can be amino acid mono-oxygenase, phenylalanine hydroxylase, tryptophan hydroxylase, tyrosine hydroxylase, nitric oxide synthase, alkylglycerol monooxygenase, and/or any combination thereof.

The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of polynucleotides encoding AADC for the treatment of Parkinson's Disease.

This present invention discloses an antisense oligonucleotide for splicing adjustment of mutant dopa decarboxylase gene which is complementary to SEQ ID NO: 1. This antisense oligonucleotide can modulate alternative splicing site of mutant dopa decarboxylase gene. It is helpful to research and develop drug to treat AADC deficiency symptom. This present invention also discloses a method to use said antisense oligonucleotide in vitro.

The purpose of the present invention is to provide a recombinant host cell which is capable of efficiently and easily producing a benzylisoquinoline alkaloid (BIA), in particular, tetrahydropapaveroline, 3-hydroxycoclaurine, 3-hydroxy-N-methylcoclaurine and/or reticuline, and a method for efficiently and easily producing these BIAs using the host cell. The present invention pertains to a recombinant host cell for producing a benzylisoquinoline alkaloid (BIA), in particular, tetrahydropapaveroline (THP), 3-hydroxycoclaurine, 3-hydroxy-N-methylcoclaurine and/or reticuline, in which a wild-type aromatic aldehyde synthase (AAS) or a mutant thereof and a wild-type aromatic amino acid decarboxylase (AAAD) or a mutant thereof are expressed.

The present disclosure relates to a tyrosine hydroxylase (TH) variant lacking 60 to 120 amino acid residues at the N terminus, and a pharmaceutical composition comprising the TH variant lacking 60 to 120 amino acid residues at the N terminus and the aromatic L-amino acid decarboxylase (AADC). The present disclosure further relates to a nucleotide construct, a vector plasmid, a cell or a virus comprising the TH variant or the pharmaceutical composition, as well as use of the virus in the manufacture of a medicament for treating neurodegenerative diseases (e.g., Parkinson's Disease).